NCT05468749View on ClinicalTrials.gov

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 6, 2022

Primary Completion Date

October 20, 2022

Study Completion Date

October 27, 2022

Conditions
Renal Impairment
Interventions
DRUG

CTP-543

Single 12 mg oral dose administered on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

37920

Alliance for Multispecialty Research, LLC, Knoxville

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY

NCT05468749 - Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543 | Biotech Hunter | Biotech Hunter